An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Trial Status: active
This study is researching an experimental drug called fianlimab (also known as REGN3767),
combined with another medication called cemiplimab (also known as REGN2810), called
"study drugs". The study is focused on patients with a type of skin cancer known as
melanoma. The aim of the study is to see how safe and effective the combination of
fianlimab and cemiplimab is in treating melanoma, in comparison with the combination of
two medications, relatlimab and nivolumab, commercialized under the brand name Opdualag™
and approved for the treatment of melanoma in adults and children.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drugs.
- How much study drug is in the blood at different times.
- Whether the body makes antibodies against the study drugs (which could make the drug
less effective or could lead to side effects)
Inclusion Criteria
Key Inclusion Criteria:
1. Participants with histologically confirmed unresectable stage III and stage IV
(metastatic) melanoma per American Joint Committee on Cancer (AJCC), eighth revised
edition.
2. Participants must not have received prior systemic therapy for unresectable or
metastatic melanoma as described in the protocol.
3. Measurable disease per RECIST version 1.1.
4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤1
5. Adequate bone marrow, hepatic, and kidney function
6. Known B-Rapidly Accelerated Fibrosarcoma protein (BRAF) V600 mutation status or
submitted sample for BRAF V600 mutation assessment as described in the protocol
Key Exclusion Criteria:
Medical Conditions:
1. Uveal, acral or mucosal melanoma.
2. Ongoing or recent (within 2 years) evidence of an autoimmune disease that required
systemic treatment with immunosuppressive agents as described in the protocol.
3. Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B (HBV),
or hepatitis C virus (HCV) infection; or diagnosis of immunodeficiency that is
related to, or results in chronic infection. Mild cancer-related immunodeficiency
(such as immunodeficiency treated with gamma globulin and without chronic or
recurrent infection) is allowed.
Prior/Concomitant Therapy:
4. Prior immune checkpoint inhibitor therapy other than anti-PD1/PD-L1 as described in
the protocol
5. Systemic immune suppression as described in the protocol.
Other Comorbidities:
6. Participants with a history of myocarditis.
7. Troponin T (TnT) or troponin I (TnI) >2x institutional upper limit of normal (ULN).
8. Active or untreated brain metastases or spinal cord compression as described in the
protocol.
Note: Other protocol-defined Inclusion/ Exclusion Criteria apply.
Additional locations may be listed on ClinicalTrials.gov for NCT06246916.
